Goldman Sachs lowered the firm’s price target on Calumet (CLMT) to $21 from $22 but keeps a Buy rating on the shares ahead of its Q4 results. The key area of focus in investor conversations continues to center around the MaxSAF project, with discussions primarily around the path towards 300M gallons of SAF annual production where the company recently received its first drawdown of 782M from the $1.4B guaranteed loan facility from the DOE, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet up after saying $782M in funding from DOE seen completed next week
- Calumet Specialty Products: Buy Rating Driven by DOE Loan Progress and Renewable Growth Prospects
- Calumet downgraded to Sell from Neutral at UBS
- Calumet Specialty Products put volume heavy and directionally bearish
- Calumet Specialty Products call volume above normal and directionally bullish